ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
INVA | Beta thalassemia patients suffering from iron overload | Phase 3 | 2019-11-25 00:00:00 | Development to be discontinued due to lack of efficacy - November 25, 2019. | -1 |
PRVB | Type 1 diabetes | Approved | 2022-11-17 00:00:00 | Approved November 17, 2022. | 1 |
PTGX | Plaque psoriasis | Phase 2b | 2023-07-05 00:00:00 | Phase 2b trial met all primary and secondary efficacy endpoints, noted July 5, 2023. | 0 |
ADCT | High-Risk Relapsed/Refractory Follicular Lymphoma | Phase 2 | 2023-07-11 00:00:00 | Phase 2 trial enrollment voluntarily paused after recent review of aggregate data of the 40 patients enrolled in the trial and consultation with the Data Monitoring Committee (DMC) which signaled potentially excessive respiratory-related events, noted July 11, 2023. | -1 |
BHVN | Alzheimer鈥檚 disease | Phase 2/3 | 2021-01-18 00:00:00 | Phase 2/3 top-line data did not meet co-primary endpoints - January 18, 2021. | 1 |
IMUX | Ulcerative colitis | Phase 2 | 2023-04-05 00:00:00 | Additional Phase 2 data reported a dose-linear increase in clinical remission as compared to placebo at week 50 with an exploratory statistical analysis confirming that the 30 mg dose of vidofludimus calcium was statistically superior in achieving clinical remission, with a 33.7% absolute improvement over placebo, noted April 5, 2023. | 1 |
AZN | Risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) | Approved | 2023-05-09 00:00:00 | Approved May 9, 2023. | 1 |
PHGE | Acne | Phase 2 | 2021-11-15 00:00:00 | Program to be discontinued to focus resources on CF and AD programs, noted November 15, 2021. | -1 |
BLRX | Solid tumors | Phase 1/2 | 2022-01-24 00:00:00 | Phase 1/2a enrollment completed January 24, 2022. | 0 |
VIR | Hepatitis B | Phase 2 | 2023-06-24 00:00:00 | Phase 2 part A preliminary 48-week post-treatment safety, tolerability and antiviral activity data demonstrated that combination resulted in a 2.7-3.1 log10 IU/mL decline in HBsAg levels at the end of treatment, noted June 24, 2023. | 1 |
ONTX | Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma | Phase 2 | 2023-10-12 00:00:00 | Phase 2 data shared at the EADV reported that two patients achieved complete cutaneous responses of 12 months or more, one patient experienced metastatic disease progression, and one patient remains on study, noted October 12, 2023. | 1 |
VIRI | Fibromyalgia | Phase 2b | 2022-09-19 00:00:00 | Phase 2b trial did not meet primary endpoint, noted September 19, 2022. | 1 |
ETON | Pediatric adrenal insufficiency (AI) | Approved | 2020-09-29 00:00:00 | FDA approval announced September 29, 2020. | 1 |
GSK | Measles, mumps and rubella (MMR) | Approved | 2022-06-06 00:00:00 | Approved June 6, 2022. | 1 |
BHC | Allergic conjunctivitis | Approved | 2020-09-25 00:00:00 | FDA approval announced September 25, 2020. | 1 |
INAB | Glioblastoma | Phase 2 | 2023-06-05 00:00:00 | Data presented at ASCO 2023 showed that 100% of treated patients to date have exceeded historical median progression-free survival, with two patients that received three doses remaining progression-free at 23.5 and 19.4 months, respectively noted on June 5, 2023. | 1 |
PFE | Children - growth hormone deficiency | Approved | 2023-06-28 00:00:00 | FDA Approved on June 28, 2023. | 1 |
TAK | Higher-risk myelodysplastic syndromes (HR-MDS), chronic myelomonocytic leukemia (CMML) and low-blast acute myeloid leukemia (AML) | Phase 3 | 2021-09-01 00:00:00 | Phase 3 data did not meet primary endpoint September 1, 2021. | 1 |
SRPT | Duchenne muscular dystrophy | Approved | 2016-09-19 00:00:00 | Approved September 19, 2016. | 1 |
ABUS | Chronic Hepatitis B | Phase 2a | 2023-06-21 00:00:00 | Phase 2a preliminary data presented at EASL data suggested that the addition of IFN to AB-729 treatment was generally well tolerated and appears to result in continued HBsAg declines in some patients, noted June 21, 2023. | 1 |
SCNI | Universal flu vaccine | Phase 3 | 2020-10-23 00:00:00 | Phase 3 trial did not meet endpoints - October 23, 2020. | 1 |
CORT | Ovarian cancer | Phase 2 | 2022-06-06 00:00:00 | Phase 2 results reported a median 7.3 months of progression-free survival, a median of 5.6 months for duration of response, and 17.9 months for overall survival, noted June 6, 2022. | 0 |
GPCR | Healthy Volunteers | Phase 1 | 2023-05-23 00:00:00 | First-in-human data reported that pharmacokinetic exposure was generally dose proportional with minimal accumulation after once daily dosing with ANPA-0073 across the dose range, noted May 22, 2023. | 0 |
GSK | COVID-19 vaccine | Phase 3 | 2021-12-15 00:00:00 | Phase 3 data reported that the vaccine is well tolerated, with a safety profile similar to currently approved COVID-19 vaccines, noted December 15, 2021. | 1 |
MOLN | Solid Tumors | Phase 1 | 2023-11-03 00:00:00 | Phase 1 data presented at SITC continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment, noted November 3, 202 | 1 |
ICVX | RSV/human Metapneumovirus (hMPV) | Phase 1 | 2023-05-23 00:00:00 | Phase 1 data reported that the proportion of subjects experiencing any systemic AE within seven days was 25-41%, and similar to 35% for placebo, with induced geometric mean titers (GMTs) in RSV-A neutralizing antibody titers (nAbs) of up to approximately 16,100 IU/mL compared to approximately 2,600 IU/mL for placebo at Day 28, noted May 23, 2023. | 0 |
BGNE | Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | 2021-06-04 00:00:00 | Phase 3 poster at ASCO June 4, 2021 noted median OS of 8.6 months compared to 6.3 months in the chemotherapy arm. | 0 |
TNGX | Solid Tumors | Phase 1/2 | 2023-07-10 00:00:00 | Phase 1/2 dosing initiated, noted July 10, 2023. | 0 |